These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27029828)

  • 1. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.
    Luz PM; Girouard MP; Grinsztejn B; Freedberg KA; Veloso VG; Losina E; Struchiner CJ; MacLean RL; Parker RA; Paltiel AD; Walensky RP
    J Int AIDS Soc; 2016; 19(1):20623. PubMed ID: 27029828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The survival benefits of antiretroviral therapy in South Africa.
    April MD; Wood R; Berkowitz BK; Paltiel AD; Anglaret X; Losina E; Freedberg KA; Walensky RP
    J Infect Dis; 2014 Feb; 209(4):491-9. PubMed ID: 24307741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized life expectancy and treatment benefit index of antiretroviral therapy.
    Xiao Y; Sun X; Tang S; Zhou Y; Peng Z; Wu J; Wang N
    Theor Biol Med Model; 2017 Jan; 14(1):1. PubMed ID: 28100241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study.
    Smiley CL; Rebeiro PF; Cesar C; Belaunzaran-Zamudio PF; Crabtree-Ramirez B; Padgett D; Gotuzzo E; Cortes CP; Pape J; Veloso VG; McGowan CC; Castilho JL;
    Lancet HIV; 2021 May; 8(5):e266-e273. PubMed ID: 33891877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
    Carriquiry G; Fink V; Koethe JR; Giganti MJ; Jayathilake K; Blevins M; Cahn P; Grinsztejn B; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; McGowan CC; Shepherd BE
    J Int AIDS Soc; 2015; 18(1):20016. PubMed ID: 26165322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention and mortality outcomes from a community-supported public-private HIV treatment programme in Myanmar.
    Mburu G; Paing AZ; Myint NN; Di W; Thu KH; Ram M; Hoffmann CJ; Wang B; Naing S
    J Int AIDS Soc; 2016; 19(1):20926. PubMed ID: 27784509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
    De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
    Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival in HIV treatment programmes in Asia.
    De La Mata NL; Kumarasamy N; Khol V; Ng OT; Van Nguyen K; Merati TP; Pham TT; Lee MP; Durier N; Law M
    Antivir Ther; 2016; 21(6):517-527. PubMed ID: 26961354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.
    Losina E; Schackman BR; Sadownik SN; Gebo KA; Walensky RP; Chiosi JJ; Weinstein MC; Hicks PL; Aaronson WH; Moore RD; Paltiel AD; Freedberg KA
    Clin Infect Dis; 2009 Nov; 49(10):1570-8. PubMed ID: 19845472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of genotype testing for primary resistance in Brazil.
    Luz PM; Morris BL; Grinsztejn B; Freedberg KA; Veloso VG; Walensky RP; Losina E; Nakamura YM; Girouard MP; Sax PE; Struchiner CJ; Paltiel AD
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):152-61. PubMed ID: 25415289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
    Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
    J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].
    Ding YY; Jia WQ; Wang JS; Dong SL; Yang QH; Zhou RY; Qu SX; Lu LX; Wei J; Qiao XC; Gao MY; Guo XL; Zhang TJ; Wu ZY; He N
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec; 29(12):1176-80. PubMed ID: 19173958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India.
    Rajasekaran S; Jeyaseelan L; Raja K; Vijila S; Krithigaipriya KA; Kuralmozhi R
    J Postgrad Med; 2009; 55(4):261-6. PubMed ID: 20083872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
    Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
    AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study.
    Nsanzimana S; Remera E; Kanters S; Chan K; Forrest JI; Ford N; Condo J; Binagwaho A; Mills EJ
    Lancet Glob Health; 2015 Mar; 3(3):e169-77. PubMed ID: 25701995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.
    Cescon A; Patterson S; Davey C; Ding E; Raboud JM; Chan K; Loutfy MR; Cooper C; Burchell AN; Palmer AK; Tsoukas C; Machouf N; Klein MB; Rourke SB; Rachlis A; Hogg RS; Montaner JS;
    J Int AIDS Soc; 2015; 18(1):20024. PubMed ID: 26443752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.